| scholarly article | Q13442814 |
| P50 | author | Antonio Cigliano | Q43122575 |
| P2093 | author name string | Xin Chen | |
| Meng Xu | |||
| Diego F Calvisi | |||
| Hui Cao | |||
| Frank Dombrowski | |||
| Zhong Xu | |||
| Silvia Ribback | |||
| Junjie Hu | |||
| Maria G Pilo | |||
| Zixuan Shao | |||
| P2860 | cites work | Multiplex genome engineering using CRISPR/Cas systems | Q24609428 |
| mTOR signaling in growth control and disease | Q24634174 | ||
| AKT/PKB signaling: navigating downstream | Q24657857 | ||
| Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends | Q26830194 | ||
| Global cancer statistics, 2012 | Q27860501 | ||
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| mTOR inhibitors in cancer therapy | Q28079129 | ||
| Met, metastasis, motility and more | Q28235183 | ||
| CRISPR-Cas systems for editing, regulating and targeting genomes | Q29615781 | ||
| Targeting PI3K signalling in cancer: opportunities, challenges and limitations | Q29617685 | ||
| PI3K and cancer: lessons, challenges and opportunities | Q30080017 | ||
| The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma | Q46081339 | ||
| Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. | Q53347351 | ||
| Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma | Q81128776 | ||
| The critical role of AKT2 in hepatic steatosis induced by PTEN loss | Q33816356 | ||
| Synergistic role of sprouty2 inactivation and c-Met up-regulation in mouse and human hepatocarcinogenesis | Q34062598 | ||
| IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. | Q34102411 | ||
| Hepatic mTORC2 activates glycolysis and lipogenesis through Akt, glucokinase, and SREBP1c | Q34269920 | ||
| CRISPR-mediated direct mutation of cancer genes in the mouse liver | Q34353586 | ||
| Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype | Q34619635 | ||
| Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial | Q34663499 | ||
| Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. | Q34672477 | ||
| c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma | Q35235798 | ||
| In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. | Q35250612 | ||
| SKP2 cooperates with N-Ras or AKT to induce liver tumor development in mice | Q35273519 | ||
| Distinct pathways of genomic progression to benign and malignant tumors of the liver. | Q35970966 | ||
| Targeting the HGF/c-MET Pathway in Hepatocellular Carcinoma | Q36093497 | ||
| Temporal changes in PTEN and mTORC2 regulation of hematopoietic stem cell self-renewal and leukemia suppression | Q36248716 | ||
| Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis | Q36384467 | ||
| Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice. | Q36560210 | ||
| Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans. | Q36922232 | ||
| Spontaneous Hepatocellular Carcinoma after the Combined Deletion of Akt Isoforms. | Q37038522 | ||
| Role of cyclin D1 as a mediator of c-Met- and beta-catenin-induced hepatocarcinogenesis | Q37065772 | ||
| Pivotal role of mTOR signaling in hepatocellular carcinoma | Q37183244 | ||
| Pathogenesis of hepatocellular carcinoma and molecular therapies. | Q37456002 | ||
| Akt-mediated foxo1 inhibition is required for liver regeneration. | Q37525730 | ||
| Potentiation of the anticancer effects of everolimus using a dual mTORC1/2 inhibitor in hepatocellular carcinoma cells | Q37709404 | ||
| PTEN in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and cancer. | Q37749362 | ||
| Targeting MET in cancer: rationale and progress | Q37978193 | ||
| Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway | Q38170894 | ||
| Hydrodynamic transfection for generation of novel mouse models for liver cancer research | Q38183539 | ||
| Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. | Q38534459 | ||
| Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial | Q38785510 | ||
| Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice and humans | Q38827148 | ||
| mTORC1 and mTORC2 in cancer and the tumor microenvironment | Q38982579 | ||
| Expansion of hepatic tumor progenitor cells in Pten-null mice requires liver injury and is reversed by loss of AKT2. | Q39656536 | ||
| Activated mutant forms of PIK3CA cooperate with RasV12 or c-Met to induce liver tumour formation in mice via AKT2/mTORC1 cascade | Q42468960 | ||
| Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma | Q43049041 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P304 | page(s) | e417 | |
| P577 | publication date | 2018-01-05 | |
| P1433 | published in | Experimental and Molecular Medicine | Q15758292 |
| P1476 | title | Loss of Pten synergizes with c-Met to promote hepatocellular carcinoma development via mTORC2 pathway | |
| P478 | volume | 50 |
| Q91857825 | Activated Fibroblast Program Orchestrates Tumor Initiation and Progression; Molecular Mechanisms and the Associated Therapeutic Strategies |
| Q92898129 | Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans |
| Q90383817 | Experimental Models to Define the Genetic Predisposition to Liver Cancer |
| Q64053269 | Functional role of SGK3 in PI3K/Pten driven liver tumor development |
| Q58612842 | Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy |
| Q64999337 | Mito-Nuclear Communication in Hepatocellular Carcinoma Metabolic Rewiring. |
| Q58693431 | Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma |
| Q89861316 | Molecular Signaling Pathways and Therapeutic Targets in Hepatocellular Carcinoma |
| Q92192093 | Molecular links between non-alcoholic fatty liver disease and hepatocellular carcinoma |
| Q89531796 | Oncogene-dependent function of BRG1 in hepatocarcinogenesis |
| Q94566583 | Role of the mTOR pathway in liver cancer: from molecular genetics to targeted therapies |
| Q90240699 | Validation of miR-20a as a Tumor Suppressor Gene in Liver Carcinoma Using Hepatocyte-Specific Hyperactive piggyBac Transposons |
Search more.